Follow us on Twitter
Below you will find current and archived press releases for your associated company. Navigate by selecting the year in the list below and click on the press release you want to read. Distribution takes place with a maximum of five minutes delay from press release.
New facility up and running
While the inauguration of Nanexa’s new premises showed both the high class GMP classified facil...
Den 9 juni invigdes Nanexas nya satsning i Uppsala Business Park – en pilotanläggning på 900 kvadratmeter som inhyser kontor, R&D-la...
The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on June 9, 2022, at which meeting submitted proposals were passed...
Nanexa AB today announced that the company has been granted funding under the VINNOVA project "Verification in Test Center, Part III...
Aktieägarna i Nanexa AB (publ), org.nr 556833–0285 (”Bolaget”) kallas härmed till årsstämma torsdagen den 9 juni 2022, kl 14:00, på ...
Nanexa AB (publ) today announced that the European Patent Office (EPO) has granted the company’s patent application relating to the ...
Med en plan framåt för NEX-18 och nya produktionsanläggningen snart i drift ser vi ljust på chanserna för ett avtal om plattformslic...
Nanexa AB (publ) meddelar idag att årsredovisningen för 2021 har offentliggjorts och finns tillgänglig på bolagets hemsida www.nanexa.com/fi...
Positive development in the product projects and in the patent portfolio
Significant events during the fi...
Nanexa AB (publ) offentliggör imorgon, den 20 april 2022, sin rapport för första kvartalet 2022 och bjuder in till presentation av r...
Nanexa AB today announced that the United States District Court for the District of Delaware in Nanexa AB v. VitriVax, Inc. C.A. No....
Nanexa AB today announced that CEO David Westberg has been invited as speaker and the company also got three abstracts approved for ...
Nanexa meddelar i dag att bolaget är ett av tre företag som nominerats i kategorin Årets Innovation till Företagsgalan i Uppsala och...
Additional evaluation agreement and positive results in preclinical investigation of NEX-18
Significant e...
Efter att Nanexa funnit en lösning och väg framåt med den pausade fas I-studien med NEX-18 står det samtidigt klart att återstarten ...
Nanexa AB (publ) today announces that the company's preclinical investigation indicates the cause and a potential solution to the mo...
Nanexa AB (publ) today announced that the company has received a new patent in the USA. The newly issued patent (US 11,214,865 B2) r...
